Evommune, Inc.
EVMN
$24.09
-$0.94-3.76%
NYSE
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -100.00% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -100.00% | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -100.00% | -- | |||
| SG&A Expenses | 152.45% | 9.92% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 27.38% | 1.45% | |||
| Operating Income | -122.96% | 42.04% | |||
| Income Before Tax | -126.64% | 8.04% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -126.64% | 8.04% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -126.64% | 8.04% | |||
| EBIT | -122.96% | 42.04% | |||
| EBITDA | -125.78% | 42.45% | |||
| EPS Basic | 82.29% | 8.29% | |||
| Normalized Basic EPS | 82.29% | 8.29% | |||
| EPS Diluted | 82.29% | 8.29% | |||
| Normalized Diluted EPS | 82.29% | 8.29% | |||
| Average Basic Shares Outstanding | 1,179.99% | 0.28% | |||
| Average Diluted Shares Outstanding | 1,179.99% | 0.28% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||